What is dasatinib and what is it used for?

Dasatinib (Dasatinib) is a targeted therapy drug, a second-generation tyrosine kinase inhibitor, mainly used to treat Philadelphia chromosome-positive (Ph+) hematological tumors. Its mechanism of action is to inhibit the activity of BCR-ABL fusion protein and interfere with the growth and proliferation of tumor cells, thereby combating specific types of leukemia. The clinical application of dasatinib is mainly concentrated in two major groups: adult patients and pediatric patients.

For adult patients, the indications for dasatinib include newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The drug can effectively control the disease when patients are in the chronic phase. In addition, dasatinib is also suitable for patients who still have resistance or intolerance after multiple treatments. This includes patients with chronic, accelerated, or myeloid and lymphoblastic stages of Ph+CML, as well as patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Studies have shown that patients taking dasatinib generally achieve better results, especially when resistance to first-line treatments such as imatinib is overcome.

In pediatric patients, dasatinib also shows good application potential. Dasatinib can be considered for patients 1 year old and older if they are diagnosed with chronic phase Ph+CML or combined with chemotherapy in newly diagnosed Ph+ALL. This provides new treatment options for childhood leukemia patients and helps improve their prognosis.

The advantage of dasatinib in clinical application is not only its efficient anti-tumor effect, but also its relatively good tolerability. Compared with traditional chemotherapy drugs, dasatinib's side effects are usually milder, and patients' quality of life has been improved accordingly. However, despite its high safety profile, possible side effects need to be monitored during use, including bone marrow suppression, heart problems, and gastrointestinal discomfort.